Actively Recruiting
Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study
Led by Ruijin Hospital · Updated on 2025-04-23
5000
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand how systemic and local cardiometabolic risk factors affect heart structure, function, and clinical outcomes in patients with heart failure (HF). It includes patients with various HF types: reduced, mildly reduced, preserved, and improved ejection fraction. The study combines retrospective clinical data from the past 10 years with a 5-year prospective follow-up to capture disease progression and risk patterns. The study evaluates metabolic factors like blood lipids, glucose levels, and insulin resistance, as well as localized fat deposits around the heart (epicardial and perivascular adipose tissue) measured by advanced imaging techniques such as cardiac MRI or CT. These factors are analyzed in relation to heart geometry changes, functional measures, transitions between HF types, and major cardiovascular events including re-hospitalization and cardiovascular death. Participants undergo initial standardized assessments including blood tests, echocardiography, and imaging, followed by clinical and biochemical evaluations every three months during the prospective phase. Retrospective data include historical imaging and lab results. Researchers will measure changes in heart function and structure at 12 months and track major cardiovascular events over 5 years. The study aims to improve risk assessment and guide personalized treatment for heart failure patients.
CONDITIONS
Brief Title
Cardiometabolic evalUation REgistry of Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of chronic heart failure (NYHA class II to IV)
- Includes all heart failure types: reduced, mildly reduced, preserved, and improved ejection fraction
- Presence of heart failure symptoms and/or signs
- Evidence of left ventricular ejection fraction as per HF type criteria
- For HFpEF, objective evidence of cardiac structural or functional abnormalities with elevated natriuretic peptide levels
You will not qualify if you...
- Estimated life expectancy of 1 year or less
- Pregnant, breastfeeding, or planning pregnancy within one year
- Poor compliance or inability to attend follow-up visits
- Mental or physical inability to provide written informed consent
- Unwillingness to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline assessment period
Participants undergo baseline assessments including blood biomarkers, echocardiography, and advanced cardiac imaging (CT or MRI) to evaluate cardiometabolic risk factors and cardiac structure and function.
1 baseline visit (in-person)
Duration - Up to 5 years
Participants are followed prospectively with routine clinical, biochemical, and imaging evaluations every 3 months to monitor changes in cardiac function, cardiometabolic factors, and clinical outcomes over time.
Quarterly visits for up to 5 years
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China, 200025
Actively Recruiting
Research Team
C
Chendie Yang, M.D., Ph.D.
X
Xiaoqun Wang, M.D., Ph.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here